{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:54:38Z","timestamp":1787496878094,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    Levodopa remains the cornerstone of symptomatic treatment in Parkinson\u2019s disease, providing substantial motor benefit and improved quality of life. While epidemiological studies have suggested improved survival in the modern levodopa era compared with the pre-levodopa era, these observations derive primarily from observational cohorts rather than randomized trials. Yet many patients experience severe functional decline after 5\u201310\u202fyears, a paradox that challenges the reputation of our most potent therapy. Similar divergences between early symptomatic benefit and adverse long-term outcomes have been observed in other areas of medicine. For example, positive inotropic agents such as milrinone improved short-term exercise tolerance in heart failure but were later associated with increased mortality in long-term trials. Antiarrhythmic agents encainide and flecainide effectively suppressed ventricular arrhythmias yet increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). In diabetes, intensive glucose lowering strategies improved metabolic control but increased cardiovascular mortality in the ACCORD trial, and earlier studies of tolbutamide in the University Group Diabetes Program (UGDP) also suggested excess cardiovascular deaths despite improved glycemic control. These examples illustrate how therapies with clear short-term physiological benefits may reveal unanticipated risks when evaluated over longer time horizons. Similarly, the long-term use of levodopa may introduce a cumulative burden of complications that may independently accelerate decline. We propose the conceptual framework of\n                    <jats:italic>levodopa-accelerated frailty<\/jats:italic>\n                    as a testable hypothesis to explore this possibility. This framework synthesizes evidence across seven pathways that may interact or overlap in contributing to frailty: dyskinesia, psychosis, orthostatic hypotension, weight loss, impulse control disorders, sleep disturbances, and elevated homocysteine. Each complication has been associated with increased risks of dementia, hospitalization, falls, or mortality in observational studies, with reported hazard ratios generally ranging from approximately 1.5 to over 6. Together, they form a synergistic web of decline that may transform a highly effective symptomatic therapy into a contributor to late-stage vulnerability. This hypothesis reframes a potential therapeutic paradox: a treatment that improves early symptomatic outcomes may also interact with mechanisms that contribute to frailty later in the disease course. The clinical implication is not levodopa phobia, but a healthspan-preservation strategy focused on minimizing cumulative iatrogenic burden. This involves adhering to the lowest effective dose, continuous reassessment, and integration with exercise, nutrition, and adjunctive therapies. Recognizing this potential pattern of levodopa-accelerated frailty may help reconcile the discrepancy between early symptomatic success and the later emergence of vulnerability. We emphasize that this model is a hypothesis and call for long-term, prospective studies to test whether cumulative levodopa exposure contributes to frailty and reduced healthspan.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2026.1798514","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:51:13Z","timestamp":1776261073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Levodopa-accelerated frailty: a hypothesis for a cumulative iatrogenic burden in Parkinson\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Claus","family":"Skaaning","sequence":"first","affiliation":[{"name":"Independent Researcher","place":["Aalborg, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Gray","year":"2014","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/mds.29796","article-title":"Long-term follow-up of the LEAP study: early versus delayed levodopa in early Parkinson's disease","volume":"39","author":"Frequin","year":"2024","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson's disease: current controversies","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000492572","article-title":"Prevalence and associated factors of sarcopenia and frailty in Parkinson's disease: a cross-sectional study","volume":"65","author":"Peball","year":"2019","journal-title":"Gerontology"},{"key":"ref8","first-page":"6","article-title":"Frailty in Parkinson's disease: a systematic review","volume":"76","author":"Tan","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"ref9","first-page":"109","article-title":"Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management","volume":"2","author":"Aquino","year":"2015","journal-title":"Mov Disord Clin Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e1094","DOI":"10.1212\/WNL.0000000000007189","article-title":"Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD","volume":"92","author":"Lee","year":"2019","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","article-title":"Range of neuropsychiatric disturbances in patients with Parkinson's disease","volume":"70","author":"Aarsland","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3233\/JPD-213035","article-title":"Incidence, prevalence, and mortality of psychosis associated with Parkinson's disease (1991\u20132010)","volume":"12","author":"Stang","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0246121","DOI":"10.1371\/journal.pone.0246121","article-title":"Increased risk of falls and fractures in patients with psychosis and Parkinson disease","volume":"16","author":"Forns","year":"2021","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1274821","DOI":"10.3389\/fnagi.2023.1274821","article-title":"Risk of hospitalization in synucleinopathies and impact of psychosis","volume":"15","author":"Turcano","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1136\/jnnp.2003.029413","article-title":"Frequency of orthostatic hypotension in a community-based cohort of patients with Parkinson's disease","volume":"75","author":"Allcock","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1161\/01.CIR.98.21.2290","article-title":"Orthostatic hypotension predicts mortality in elderly men: the Honolulu heart program","volume":"98","author":"Masaki","year":"1998","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.parkreldis.2017.11.344","article-title":"Orthostatic hypotension in Parkinson disease: impact on health care utilization","volume":"8","author":"Merola","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"ref19","first-page":"438","article-title":"The clinical significance of weight loss in Parkinson's disease","volume":"35","author":"Sharma","year":"2006","journal-title":"Age Ageing"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.parkreldis.2006.07.002","article-title":"Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD)","volume":"21","author":"Uc","year":"2006","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/JPD-240181","article-title":"Association between body mass index changes and all-cause mortality in Parkinson's disease","volume":"17","author":"Yoon","year":"2024","journal-title":"J Mov Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"80","author":"O'Sullivan","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fneur.2018.00654","article-title":"Impulse control disorder in Parkinson's disease: a meta-analysis of cognitive, affective, and motivational correlates","volume":"9","author":"Martini","year":"2018","journal-title":"Front Neurol"},{"key":"ref24","first-page":"606","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: from pathology to behavior","volume":"23","author":"Cilia","year":"2012","journal-title":"Neuroreport"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e13936","DOI":"10.1111\/jsr.14240","article-title":"Sleep \"ON\", sleep better! Positive effects of levodopa on sleep behaviour in people with Parkinson's disease","volume":"33","author":"de Carvalho Costa","year":"2024","journal-title":"J Sleep Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1007\/s00415-021-10419-7","article-title":"Effects of levodopa on quality of sleep and nocturnal movements in Parkinson\u2019s disease","volume":"268","author":"Schaeffer","year":"2021","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"880583","DOI":"10.3389\/fneur.2022.880583","article-title":"Association between dopaminergic medications and the evolution of REM sleep behavior disorder in Parkinson's disease","volume":"13","author":"Cao","year":"2022","journal-title":"Front Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e1024","DOI":"10.1212\/WNL.0000000000006134","article-title":"REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease","volume":"91","author":"Liguori","year":"2018","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40120-025-00800-3","article-title":"Update on the present and future pharmacologic treatment of Parkinson\u2019s disease","volume":"14","author":"M\u00fcller","year":"2025","journal-title":"Neurol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/cells11091511","article-title":"Effects of one-day application of levodopa\/carbidopa plus Entacapone or Opicapone on homocysteine metabolism in Parkinson\u2019s disease patients","volume":"11","author":"M\u00fcller","year":"2022","journal-title":"Cells"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.m146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1212\/WNL.0000000000003452","article-title":"Effects of orthostatic hypotension on cognition in Parkinson disease","volume":"88","author":"Cronin-Golomb","year":"2017","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2022.05.004","article-title":"Frailty in Parkinson's disease and its association with early dementia: a longitudinal study","volume":"99","author":"Borda","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"ref35","first-page":"747","article-title":"Parkinson's disease and its management: part 4: treatment of advanced Parkinson's disease","volume":"40","author":"DeMaagd","year":"2015","journal-title":"PT"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.mayocp.2017.12.015","article-title":"Slowing Parkinson's disease progression: a plan for action","volume":"93","author":"Ahlskog","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"ref40","first-page":"747","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes","volume":"19","year":"1970","journal-title":"Diabetes"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1798514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:51:15Z","timestamp":1776261075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1798514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":40,"alternative-id":["10.3389\/fneur.2026.1798514"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1798514","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1798514"}}